MedTrace Logo

Prostate Cancer Risk in Firefighters

NCT03893123 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 4500

Last updated 2020-03-04

No results posted yet for this study

Summary

Firefighters have been shown to be at increased risk for various types of cancer, including prostate cancer. This study will try to explore possible reasons for this increase in risk. A study group at the Cancer Registry of Norway is creating a cohort of Norwegian firemen employed from 1960 onwards. A job exposure matrix (JEM) is also being constructed, examining different types of exposure to potentially cancer-inducing agents and activities, and how these have changed historically. Examples include exposure to fire-smoke, shiftwork, diesel exhaust and regular health check-ups. By linking the cohort with data from the Cancer Registry of Norway and the JEM the investigators can examine which exposure assessments, if any, are related to an increased risk of prostate cancer.

Conditions

  • Prostatic Cancer

Interventions

OTHER

Observational study, prostate cancer is outcome of interest

Observational study

Sponsors & Collaborators

  • Norwegian Institute of Public Health

    collaborator OTHER_GOV

  • Extrastiftelsen

    collaborator OTHER

  • National Institute of Occupational Health

    collaborator UNKNOWN

  • Norwegian Confederation of Trade Unions

    collaborator UNKNOWN

  • Fagforbundet

    collaborator UNKNOWN

  • Gjensidige Foundation

    collaborator UNKNOWN

  • Norwegian Cancer Society

    collaborator OTHER

  • Norwegian Firefighters Fight Cancer

    collaborator UNKNOWN

  • Norwegian Labour Inspection Authority

    collaborator UNKNOWN

  • Oslo University Hospital

    lead OTHER

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-02-01
Completion
2021-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03893123 on ClinicalTrials.gov